• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Alcidion Posts Record FY21 Revenue but Shares Slide (ASX:ALC)

Like 0

By Kiryll Prakapenka, Tuesday, 24 August 2021

The Alcidion Group [ASX:ALC] reported record revenue for FY21 of $25.9 million. The record revenue was not enough to increase the ALC shares price, with the Alcidion stock currently down 1.5%.

The Alcidion Group Ltd [ASX:ALC] reported record revenue for FY21 of $25.9 million.

The record revenue was not enough to increase ALC’s share price, with the Alcidion share price currently down 1.5%.

ASX ALC - Alcidion Share Price ChartSource: Tradingview.com

Despite today’s slump, ALC shares have still gained 155% over the last 12 months.

Alcidion’s record revenue

Alcidion — providing technology solutions to the healthcare industry — reported FY21 revenue of $25.9 million, a jump of 39% on FY20.

Recurring revenue also increased by 56% to $16.3 million.

Alcidion attributed this to an ‘accelerated growth plan to capture the growing UK market.’

The growth plan saw the acquisition of ExtraMed, which added new customers to the UK segment.

Additionally, ALC reported a gross profit margin of 88.3%, an 2.4% improvement over FY20’s 85.9%.

EBITDA down

Alcidion did report an EBITDA loss of $0.5 million. The company said this reflected its continued focus on scaling its business.

However, ALC noted that underlying EBITDA — which excludes M&A costs and share-based payments) was a positive $0.5 million for the year.

ALC also posted positive Operating Cash Flow of $1.5 million, which is an improvement of $3.6 million on FY20.

The company is sitting on cash reserves worth $25.0 million, which ALC said will be used for further growth and expansion.

Managing Director Kate Quirke commeted:

‘With nearly 40% growth in the past 12 months, we have secured greater market share across Australia, New Zealand and the United Kingdom, and signed important new contracts that have provided us with a solid foundation going into the new financial year.’

What’s next for the ALC share price?

In 2019, the global digital health market was worth an estimated US$175 billion.

But with an expected CAGR of almost 25% from 2019 to 2025, the digital health market is forecasted to reach nearly US$660 billion by 2025.

This is likely why Alcidion continues to invest heavily in scaling its business, as it attempts to capture a significant share of a growing market.

Alcidion thinks it is set for further sales growth across all regions in FY22, with Quirke referencing ALC’s growth opportunities:

‘We have a tremendous growth opportunity ahead of us in the new financial year as Alcidion builds on the record-breaking momentum created in FY21.

‘This will be achieved by accelerating sales across all regions.

‘We have pre-sold contracted revenue and scheduled renewals for FY22 of approximately $18M as well as an established strong sales pipeline out to FY26.’

ALC is stepping into FY22 with a strong pipeline of business with $15.1 million of contracted revenue already signed. This is 18% higher than at the same time last year.

If you’re interested in other small-caps that have the potential to disrupt traditional industries, I recommend reading the latest report from our market analyst Murray Dawes.

He just put together a report profiling seven unheralded Aussie companies developing what he thinks are extraordinary new ideas.

 

Regards,

Kiryll Prakapenka,

For Money Morning

PS: Our publication Money Morning is a fantastic place to start on your investment journey. We talk about the big trends driving the most innovative stocks on the ASX. Learn all about it here

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Kiryll Prakapenka

Kiryll’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Critical Metal Stocks: Following the Iron Ore Playbook
    By James Cooper

    How does inconceivable capex find its way into new mining projects? Answer: Higher commodity prices. James Cooper compares the iron ore boom from the early 2000s to what may lie ahead for critical minerals.

  • Copper traders: gettin’ jiggy with it
    By Callum Newman

    Copper has now broken into an all time high after threatening to do so for some time. There’s no reason to think it’s going to go down, either, if the market views Trump as serious. The race is on to buy up what you can before the tariff goes into effect.

  • Australia ain’t the USA…and that’s great!
    By Callum Newman

    The outlook for Australia and the ASX are very different to the US and US shares. Here’s why…

Primary Sidebar

Latest Articles

  • Critical Metal Stocks: Following the Iron Ore Playbook
  • Copper traders: gettin’ jiggy with it
  • Australia ain’t the USA…and that’s great!
  • The biggest infrastructure spending boom in history just kicked off
  • You Read it Here First: Great Asset Rotation Underway

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988